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ABSTRACT: pH (low) insertion peptides (pHLIP peptides)
target acidic extracellular environments in vivo due to pH-
dependent cellular membrane insertion. Two variants (Var3
and Var7) and wild-type (WT) pHLIP peptides have shown
promise for in vivo imaging of breast cancer. Two positron
emitting radionuclides (64Cu and 18F) were used to label the
NOTA- and NO2A-derivatized Var3, Var7, and WT peptides
for in vivo biodistribution studies in 4T1 orthotopic tumor-
bearing BALB/c mice. All of the constructs were radiolabeled with 64Cu or [18F]-AlF in good yield. The in vivo biodistribution of
the 12 constructs in 4T1 orthotopic allografted female BALB/c mice indicated that NO2A-cysVar3, radiolabeled with either 18F
(4T1 uptake; 8.9 ± 1.7%ID/g at 4 h p.i.) or 64Cu (4T1 uptake; 8.2 ± 0.9%ID/g at 4 h p.i. and 19.2 ± 1.8% ID/g at 24 h p.i.),
shows the most promise for clinical translation. Additional studies to investigate other tumor models (melanoma, prostate, and
brain tumor models) indicated the universality of tumor targeting of these tracers. From this study, future clinical translation will
focus on 18F- or 64Cu-labeled NO2A-cysVar3.
■ INTRODUCTION
Cancer cells, in general, prefer the glycolytic pathway of energy
production as a consequence of their deregulated proliferative
machinery and requirement for survival, resulting in excess
acidity. To maintain homeostasis, cancer cells release lactic acid,
formed during glycolytic processes, to the extracellular
environment.1−3 The release of acid lowers the extracellular
pH immediately surrounding these cells relative to the pH of
normal tissues. Due to the diﬀerential in pH gradients, a probe
marking these acidic regions in rapidly proliferating tissues can
potentially distinguish cancerous from normal tissue.
The family of pH (low) insertion peptides (pHLIP peptides)
represents a novel class of delivery agents which can target
acidic malignant tissue.4,5 The molecular mechanism of
targeting is based on the pH-dependent formation of a
transmembrane α-helix, which is accompanied by the insertion
of pHLIP peptides into the cellular membrane in environments
with low extracellular pH (Figure 1).6 Among investigated
pHLIP variants, three were under consideration for clinical
translation: wild-type (WT), variant 3 (Var3), and variant 7
(Var7).7
To date, pHLIP peptides have been conjugated to organic
dyes or positron-emitting radioisotopes for in vitro and in vivo
studies.7−11 Viola-Villegas et al. showed that DOTA-pHLIP
variants were able to target PC3-WT cancer cells in a pH-
dependent manner using 68Ga-DO3A-cysWT and 68Ga-DO3A-
cysVar7.12 Additionally, 64Cu-NOTA-Var7 showed in vivo
localization that was inversely related to measured extracellular
pH (pHe), but with limited overall tumor uptake (1.36 ± 0.43%
ID/g).12
The selection of NOTA as the chelator in the present studies
opened opportunities to explore radiolabeling strategies with a
variety of positron-emitting radiometals, as well as with 18F, for
positron emission tomography (PET) imaging.13−16 As the
previous studies with pHLIP-PET radiopharmaceuticals in
preclinical models established the proof-of-principle that the
pHLIP platform can indeed selectively target and image tumor
acidosis, our goals have now advanced to performing ﬁrst-in-
human trials. It was ﬁrst imperative, however, to optimize the
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tracer (increasing accumulation in the tumor with a
concomitant clearance from nontarget tissues) by careful
selection of the optimal radioisotope and pHLIP peptide
variant combination prior to commencing clinical studies.
In this current study, we investigated and compared the
pharmacokinetic properties of six pHLIP constructs (NOTA-
WT, NOTA-Var3, NOTA-Var7, NO2A-cysWT, NO2A-
cysVar3, and NO2A-cysVar7) labeled with two diﬀerent PET
isotopes (64Cu and 18F) using an orthotopic breast cancer
model (murine 4T1 mammary adenocarcinoma, a model of
human stage IV breast cancer) through ex vivo biodistribution
and in vivo imaging studies. In addition, the biophysical
measurements of the nonradioactive, metalated peptides were
conducted to help explain the variations observed in the animal
studies. From these studies, two lead radiopharmaceuticals
(18F-AlF-NO2A-cysVar3 and 64Cu-NO2A-cysVar3) were se-
lected and further assessed in melanoma, prostate, and brain
tumor models.
■ RESULTS
Preparing the Radiotracers. The NOTA (1,4,7-triazacy-
clononane-N′,N″,N‴-triacetic acid) chelator was conjugated to
the pHLIP variants in two ways (Figure 2). The NOTA-pHLIP
compounds contain NOTA with three carboxylic acid groups
conjugated to the N-terminus of the peptide (Figure 2A). The
NO2A-cyspHLIP compounds contain NOTA with two
carboxylic acid groups, where the third group was used to
conjugate the chelator to the peptide through the cysteine side
chain (Figure 2B). The Cu2+ and AlF2+ NOTA complexes have
an overall charge of −1 with a neutral charge at the N-terminus
of the pHLIP peptides. All complexes with the NO2A-chelates
have an overall neutral charge with the positive charge
preserved at the N-terminus of the pHLIP peptides. The
three peptide sequences are tabulated in Figure 2C.
The 64Cu radiolabeling of each of the conjugates was
achieved with >60% (isolated) yield with >93% purity
(Supporting Information); the 18F-AlF radiolabeling of each
of the conjugates was 4−50% (isolated and decay corrected to
start of synthesis) yield with >95% purity (Supporting
Information). Table S1 lists the speciﬁc activity of each
radiolabeled pHLIP peptide.
In Vivo Studies in 4T1 Tumor Models. Direct evaluation
of all 12 tracers in vivo was carried out in 4T1 orthotopic
(surgically implanted) allografted female BALB/c mice in order
to determine which compounds would be best translated into
clinical studies. Figure 3 shows the in vivo PET imaging slices at
Figure 1. Three folding states of pHLIP peptides in decreasing extracellular pH: unfolded and unbound peptide in solution (State I), unfolded
peptide loosely interacting with the membrane lipid bilayer at physiological pH (State II), and folded peptide in α-helical conformation inserted
across the membrane at low extracellular pH (State III).
Figure 2. Two chelators [(A) NOTA-pHLIP and (B) NO2A-
cyspHLIP] and (C) the peptide sequences used in this study. The
chiral centers within the chelator and linker are marked with asterisks.
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the level of the tumor at 4 h p.i. of 11 of the 12 tracers tested
and the ex vivo biodistribution in selected organs at 4 and 24 h
p.i. (%ID/g, mean ± S.D.). The corresponding maximum
intensity projections (MIPs) from the PET imaging study and
the PET imaging slices at the level of the tumor with a lower
maximum value for better visualization of the tumor at 4 h p.i.
for the 18F-AlF-NO2A-cyspHLIP constructs are collected in
Figure S1. The 4 h ex vivo biodistribution values (%ID/g, mean
± S.D.) are collected in Tables 1 and 2 for all 12
radiopharmaceuticals, and the complete biodistribution results
for all time points are tabulated in the Supporting Information
(Tables S1−1 through S13−14). Due to the ex vivo
biodistribution data for 64Cu-NOTA-Var7 and the previous
results from the imaging study of the other NOTA-pHLIP
Figure 3. Coronal PET image slices at the level of the tumor at 4 h p.i. (A) and ex vivo biodistributions in selected organs at 4 h (B) and 24 h p.i.
(C) showing diﬀerences in the tracer distribution in BALB/c female mice bearing 4T1 tumor allografts. The yellow arrowheads in (A) indicate where
the tumor is located in the mouse. The selected scale on the PET images does not allow for tumor visualization in the case of the NO2A-cysVar7
constructs. Figure S2 shows the maximum intensity projections (MIPs) for these compounds at 4 h and the slices at the level of the tumor for the
18F-AlF-NO2A-cyspHLIP constructs with a maximum value of 15%ID/g. Only ex vivo biodistribution data was obtained for 64Cu-NOTA-Var7.
Table 1. Biodistribution (%ID/g) of the Six Radiolabeled N-Terminus Derivatized NOTA-pHLIP Derivatives in 4T1
Allografted Female BALB/c Mice at 4 h p.i.
tissue
64Cu-NOTA-WT
(n = 4)
64Cu-NOTA-Var3
(n = 5)
64Cu-NOTA-Var7
(n = 4)
18F-AlF-NOTA-WT
(n = 5)
18F-AlF-NOTA-Var3
(n = 4)
18F-AlF-NOTA-Var7
(n = 5)
blood 1.192 ± 0.263 1.371 ± 0.244 0.833 ± 0.068 1.978 ± 0.192 2.201 ± 0.374 2.292 ± 0.277
heart 0.50 ± 0.04 0.49 ± 0.05 0.35 ± 0.04 0.66 ± 0.12 0.78 ± 0.08 0.78 ± 0.06
lungs 1.414 ± 0.083 1.420 ± 0.117 0.996 ± 0.066 2.049 ± 0.211 2.217 ± 0.380 2.325 ± 0.212
liver 0.904 ± 0.097 1.034 ± 0.150 0.739 ± 0.041 0.973 ± 0.213 0.923 ± 0.153 1.089 ± 0.066
spleen 0.318 ± 0.023 0.340 ± 0.032 0.279 ± 0.016 0.434 ± 0.058 0.469 ± 0.093 0.485 ± 0.029
pancreas 0.261 ± 0.066 0.279 ± 0.041 0.198 ± 0.043 0.324 ± 0.059 0.332 ± 0.020 0.373 ± 0.051
stomach 0.282 ± 0.080 0.194 ± 0.050 0.300 ± 0.076 0.518 ± 0.152 0.482 ± 0.223 0.593 ± 0.153
s. intestine 0.391 ± 0.082 0.320 ± 0.042 0.307 ± 0.077 0.820 ± 0.245 0.927 ± 0.152 0.776 ± 0.196
l. intestine 9.96 ± 3.42 7.45 ± 2.73 7.78 ± 0.61 24.06 ± 2.85 22.05 ± 2.46 22.08 ± 6.02
kidneys 6.232 ± 0.613 7.165 ± 1.126 6.790 ± 0.461 8.550 ± 1.138 8.237 ± 1.106 7.759 ± 0.658
muscle 0.166 ± 0.008 0.171 ± 0.017 0.118 ± 0.025 0.283 ± 0.041 0.282 ± 0.055 0.325 ± 0.073
bone 0.274 ± 0.051 0.339 ± 0.018 0.229 ± 0.093 0.671 ± 0.305 0.540 ± 0.119 0.571 ± 0.202
skin 0.715 ± 0.109 0.775 ± 0.102 0.563 ± 0.145 1.032 ± 0.133 1.126 ± 0.115 1.377 ± 0.148
brain 0.054 ± 0.002 0.063 ± 0.011 0.042 ± 0.004 0.100 ± 0.015 0.107 ± 0.023 0.118 ± 0.011
tumor 0.679 ± 0.025 0.649 ± 0.091 0.546 ± 0.075 1.005 ± 0.232 0.923 ± 0.119 1.105 ± 0.125
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constructs, an additional imaging study for 64Cu-NOTA-Var7
was unjustiﬁed. These data clearly indicate that all constructs
with the NO2A chelator far outperform the constructs with the
NOTA chelator. It appears that NO2A-cyspHLIP constructs
have a longer blood half-life, which results in higher targeting
and longer retention within the tumor while the radio-
pharmaceutical clears from nontarget tissues and the blood.
Biophysical Studies. With 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC) liposomes as model membranes,
our comparative biophysical investigation of the pH-dependent
interaction of NOTA-pHLIP and NO2A-cyspHLIP constructs
with the lipid bilayer indicated that NOTA constructs adopt
unfavorable conformations at the membrane surface at
physiological and low pH compared to NO2A constructs.
Although biophysical measurements are typically conducted in
solutions without the further addition of ions, we chose to
investigate the performance of these constructs in both the
absence and the presence of physiological levels of free
magnesium and calcium ions. Wild-type constructs appear to be
sensitive to the presence of divalent cations, most likely due to
the multiple protonatable aspartic and glutamic acid residues at
the inserting end of the peptide, which tend to form divalent
complexes with these ions at physiological pH. Plots
demonstrating the changes in ﬂuorescence spectra of AlF-
NOTA-Var3, Cu-NOTA-Var3, AlF-NO2A-cysVar3, and Cu-
NO2A-cysVar3 upon interaction with membranes are shown in
Figure S2.
Figure 3 shows the biodistribution of 64Cu- and 18F-NO2A
constructs in selected tissues at 4 and 24 h. As previously
reported,17 Var7 constructs exhibit the fastest blood clearance
with the highest signal in the kidneys at 4 h p.i. and kidney
clearance at later time points. Both 18F-AlF-NO2A-cysWT and
64Cu-NO2A-cysWT have slightly higher liver and spleen uptake
compared to the corresponding cysVar3 and cysVar7
conjugates. All of the NO2A constructs demonstrate a pH-
dependent interaction with the lipid bilayer of the cellular
membrane (Figures S3 and S4), but the NO2A-cysWT
constructs exhibit the highest aﬃnity to the lipid membrane
Table 2. Biodistribution (%ID/g) of the Six Radiolabeled Cysteine Derivatized NO2A-cyspHLIP Derivatives in 4T1 Allografted
Female BALB/c Mice at 4 h p.i.
tissue
64Cu-NO2A-cysWT
(n = 4)
64Cu-NO2A-cysVar3
(n = 5)
64Cu-NO2A-cysVar7
(n = 4)
18F-AlF-NO2A-cysWT
(n = 4)
18F-AlF-NO2A-cysVar3
(n = 10)
18F-AlF-NO2A-cysVar7
(n = 4)
blood 17.6 ± 0.86 15.4 ± 1.76 2.31 ± 0.18 15.9 ± 0.63 20.8 ± 1.88 1.64 ± 0.18
heart 5.52 ± 0.15 5.12 ± 0.63 2.68 ± 0.33 4.78 ± 0.53 6.29 ± 1.03 0.89 ± 0.12
lungs 12.3 ± 1.55 14.7 ± 0.93 4.21 ± 0.23 8.73 ± 0.84 11.8 ± 3.79 1.66 ± 0.07
liver 21.9 ± 0.64 10.4 ± 0.63 15.6 ± 1.58 12.6 ± 11.4 9.06 ± 1.24 2.90 ± 0.18
spleen 7.07 ± 0.44 3.45 ± 0.35 3.31 ± 0.24 5.31 ± 0.34 3.73 ± 0.66 1.19 ± 0.10
pancreas 3.00 ± 0.08 2.31 ± 0.25 1.84 ± 0.10 2.10 ± 0.43 2.44 ± 0.20 0.49 ± 0.03
stomach 1.82 ± 0.13 1.27 ± 0.35 3.33 ± 0.31 1.31 ± 0.96 1.29 ± 0.62 0.68 ± 0.10
s. intestine 4.56 ± 0.26 2.68 ± 0.24 6.37 ± 0.11 2.85 ± 0.31 2.06 ± 0.28 0.91 ± 0.03
l. intestine 4.09 ± 0.34 2.99 ± 0.20 8.19 ± 0.85 1.47 ± 0.14 2.07 ± 0.63 0.91 ± 0.12
kidneys 40.6 ± 4.04 24.0 ± 2.78 95.5 ± 11.9 59.1 ± 3.63 34.3 ± 6.91 246 ± 25.6
muscle 1.15 ± 0.08 1.10 ± 0.15 0.64 ± 0.07 1.23 ± 0.17 1.55 ± 0.27 0.35 ± 0.06
bone 3.04 ± 0.11 1.10 ± 0.14 1.57 ± 0.18 1.94 ± 0.45 1.66 ± 0.61 0.60 ± 0.12
skin 3.23 ± 0.12 3.43 ± 0.34 2.59 ± 0.05 2.85 ± 0.22 2.92 ± 0.71 1.59 ± 0.10
brain 0.62 ± 0.06 0.35 ± 0.07 0.25 ± 0.02 0.34 ± 0.06 0.52 ± 0.14 0.05 ± 0.01
tumor 11.7 ± 1.71 8.21 ± 0.86 9.07 ± 1.81 8.16 ± 0.53 10.6 ± 2.26 8.61 ± 1.21
Figure 4. pH dependent bilayer insertion of NO2A-cysVar3 constructs. Changes in intrinsic construct ﬂuorescence are used to measure the insertion
of the construct population as a function of pH (transition from State II, at high pH, to State III, at low pH). Amount of construct population in
State II is measured on the y-axis. 95% conﬁdence intervals are indicated by yellow bands (A). pH-dependence parameters are used to calculate the
percent of inserted construct population at various pH levels (B). These transitions were measured in the presence of physiological levels of free
magnesium and calcium ions (0.65 mM and 1.25 mM, respectively).
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at physiological pH. Additionally, the pK of transition from the
membrane-bound state to the inserted state is higher for
NO2A-cysWT constructs compared with NO2A-cysVar3 and
NO2A-cysVar7 constructs. This shift in pK is most likely
responsible for the higher uptake of the NO2A-cysWT
constructs by the liver and spleen.
Both 64Cu-NO2A-cysVar3 and 18F-AlF-NO2A-cysVar3 had
the highest tumoral uptake, prolonged retention in the tumor,
and minimal accumulation in other organs based on the ex vivo
biodistribution data. Figure 4 shows the pH-dependent
insertion and tabulates the percentage of the NO2A-cysVar3
construct population that is inserted in the membrane at
various pHs. The results indicate that less than 5% of the lead
compounds should be inserted into the membrane at pH 7.4
(physiological pH), whereas greater than 25% of the NO2A-
cysVar3 compounds should be inserted into the cellular
membrane at pH 6.0 (the approximate pH at the surface of
cancer cells). In addition, the membrane insertion of Var3 and
Var7 takes place at a rate 2 orders of magnitude higher than the
rate of insertion of WT.17
In Vivo Studies in Prostate, Melanoma, and Brain
Tumor Models. The two NO2A-cysVar3 compounds that
showed superior targeting of the 4T1 tumors were compared in
melanoma and prostate cancer models. Figure 5 shows the in
vivo PET images of the uptake of the two tracers in tumors at 4
and 24 h p.i. The graph in Figure 6 directly compares the
tumoral uptake of the two lead compounds at 4, 6, and 24 h p.i.
for four of the tumor models investigated in this study. Due to
the large variation in tumor size for the LNCaP tumors, the ex
vivo data shows a minimal increase in tumoral uptake over the
PC3 tumors, but both the murine B16−F10 melanoma tumors
and 4T1 breast cancer tumors showed greater uptake of the
tracers compared to the human prostate cancer models.
Because of the low uptake of the tracers in brain tissue, the
18F-AlF-NO2A-cysVar3 was also evaluated in U87MG tumor-
bearing mice. These tumors were implanted into the brain
cavity or xenografted subcutaneously on the ﬂank of nude mice.
Figure S5 shows the imaging of these tumors. The uptake in the
U87MG tumors that were implanted into the brain cavity
showed signiﬁcant uptake of the tracer in the portion of the
tumor that was outside the skull. During necropsy, these
tumors did not show signiﬁcant inﬁltration of the brain. The ex
vivo biodistribution of 18F-AlF-NO2A-cysVar3 at 6 h p.i. in the
nude mice with ﬂank tumors is included in Figure S5. In order
to conclusively determine if the uptake of 18F-AlF-NO2A-
cysVar3 was only in the portion of the tumor outside of the
skull, a group of mice with GSC 5−22 tumors orthotopically
xenografted behind an intact blood-brain barrier (BBB) were
obtained. During necropsy, these tumors had inﬁltrated half of
the brain, but there was no uptake observed in the PET image
(Figure S5).
Speciﬁc Activity Investigation. The tracers were
prepared to have comparable speciﬁc activities (approximately
100 μCi/nmol (3.7 MBq/nmol)) for most of the studies. A few
additional studies were conducted with higher and lower
speciﬁc activities in order to compare the eﬀect of speciﬁc
activity on tumoral uptake. The data sets were analyzed
individually and showed that speciﬁc activity did not impact the
biodistribution of the tracers, especially tumoral uptake. Thus,
all of the data points for similar tumor models were averaged in
aggregate (regardless of speciﬁc activity) and tabulated together
in the Supporting Information.
Tissue Autoradiography. The uptake of 64Cu-NO2A-
cysVar3 (24 h p.i.) in LNCaP and PC3 tumors was investigated
via autoradiography with viable tissue stained with hematoxylin
and eosin (H&E) to determine if the uptake was speciﬁc to
regions showing indications of metabolic stress or necrosis.
Figure 5. Slices and maximum intensity projections (MIP) from PET
images showing diﬀerences in the radiolabeled NO2A-cysVar3
distribution at 4 and 24 h in BALB/c female mice bearing orthotopic
4T1 tumor allografts, nude male mice bearing shoulder PC3 or
LNCaP xenografts, and C57Bl/6 female mice bearing orthotopic
B16−F10 tumor allografts. The yellow arrowheads indicate where the
tumor is located in the mouse.
Figure 6. Graph of the ex vivo tumor uptake of the lead radiolabeled
NO2A-cysVar3 in various tumor models at 4, 6, and 24 h p.i.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.6b00306
Bioconjugate Chem. 2016, 27, 2014−2023
2018
Interestingly, uptake of 64Cu-NO2A-cysVar3 appears to
correlate with necrotic regions in LNCaP tumors, but not in
PC3 tumors (Figure 7). This could be a result of the PC3
tumors having less necrosis overall than the LNCaP tumors in
this study. Additionally, the autoradiography shows increased
relative uptake of 64Cu-NO2A-cysVar3 (24 h p.i.) in LNCaP
over PC3 tumors (Figure S6). This ﬁnding is similar to the
results from previous studies by our group, in which both
LNCaP and PC3 tumors were investigated.10−12 H&E staining
of tumor sections from 4T1 tumors excised 5−12 days post-
inoculation show non-necrotic tumor tissue; thus, the greater
tumoral uptake of the 64Cu-NO2A-cysVar3 (according to the
ex vivo biodistribution data) does not appear to be correlated
to necrosis.
■ DISCUSSION
Two positron-emitting radionuclides (18F and 64Cu) can be
used to label NOTA-peptides for in vivo imaging. While 64Cu
(t1/2 = 12.7 h) has a moderately short half-life, the production
of 64Cu requires a higher energy cyclotron and expensive
targetry with automated radionuclidic separation which many
institutions do not currently have. Conversely, 18F (t1/2 = 109.8
min) is readily available from most medical cyclotrons and
radiopharmaceutical centers, is routinely produced at numerous
sites worldwide, and can be inexpensively concentrated for
radiolabeling. Unlike conventional nucleophilic 18F labeling of
small organic molecules, using a chelator to coordinate the
aluminum center of [18F]-AlF is straightforward and can be
done in aqueous solution.15,16
After the radiopharmaceuticals were successfully synthesized,
their ability to target cancerous tissue was directly compared in
4T1 tumor-bearing female BALB/c mice. This model of triple-
negative human stage IV breast cancer was chosen based on
previous ﬁndings in our group that the pHLIP-PET agents were
excreted through both the hepatobiliary and renal pathways and
showed very good tumor:muscle ratios.10−12 As such, breast
cancer seemed an appropriate target which is imaged in humans
away from these excretion organs. Additionally, previous results
from Serganova et al. indicated that the pH of 4T1 tumors
increases with increased size.18 Thus, the 4T1 tumors in this
study were purposely used 5−7 days after inoculation to ensure
lower tumoral pH. The ex vivo biodistribution data show that
the metalated NOTA-pHLIP variants are quickly cleared via
both the hepatobiliary and renal pathways to reduce the overall
circulating radioactivity signiﬁcantly by 12 h p.i. The rapid
excretion of the 64Cu-NOTA-pHLIP variants from the
intestines and slow elimination from the kidneys over time
indicate that the compounds are not being taken up by the cells
within these organs, but are being eliminated via these
pathways. Additionally, when comparing the 2 h ex vivo data
for kidneys-to-large intestine ratios [64Cu-NOTA-WT is 0.35 ±
0.11; 18F-AlF-NOTA-WT is 0.42 ± 0.03; 64Cu-NOTA-var3 is
0.29 ± 0.12; 18F-AlF-NOTA-var3 is 0.52 ± 0.15; 64Cu-NOTA-
var7 is 0.32 ± 0.07; 18F-AlF-NOTA-var7 is 0.55 ± 0.19], there
is no signiﬁcant diﬀerence between the excretion pathways of
variants radiolabeled with 64Cu or 18F. Perhaps the charge of
the complexes appended to the pHLIP peptides helps to
improve the elimination of these compounds, but also
decreases the likelihood of uptake in low pH environments,
such as the tumor, which may require more residence time in
the blood. The lack of tumor targeting is evident in the imaging
study results shown in Figure 3.
Conversely, the neutrally charged NO2A complexes
conjugated to the cysteine residue of pHLIP peptides (which
preserve their positive charge at the N-terminus) show
prolonged blood circulation with slower clearance, conse-
quently leading to better perfusion of the tracers in the tumor
microenvironment where they are eﬀectively trapped. The
steady increase of the tumoral uptake of each of the tracers
implies slow localization in the tumor site. The radiometalated
NO2A-cysVar7 compounds had the shortest blood retention
with similar tumoral uptake at 4 h to the other radiolabeled
compounds. This rapid blood clearance may make the
radiometalated NO2A-cysVar7 compounds useful for shorter
imaging times (tumor is visible in the slices at the tumor level in
Figure S1) as long as the tumor is suﬃciently distant from the
kidneys (the major organ visible in the MIP in Figure S1). The
rapid clearance of the Var7 constructs (noted in previous
studies17,19) may be a function of their physical characteristics.
While these compounds have pKs of insertion similar to the
NO2A-cysVar3 constructs, they are less hydrophobic than the
NO2A-cysVar3 constructs. This lower hydrophobicity results in
faster blood clearance (indicated by lower amounts of NO2A-
cysVar7 constructs in the blood at every time point). The lower
amount of radiolabeled compound in the blood for longer
periods of time may result in lower tumoral uptake of the
NO2A-cysVar7 constructs because the targeted tissue is
exposed to less of the construct. At the same time, NO2A-
Figure 7. Comparison of uptake in sections of excised tumors from
PC3 or LNCaP tumor-bearing male nude mice. The top panels are
expansions of the whole tumor sections shown below. The left-most
panels are H&E stained, the middle panels are the autoradiography,
and the right-most panels are overlays.
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cysWT compounds exhibited highest accumulation in liver and
spleen compared to NO2A-cysVar3 and NO2A-cysVar7, most
probably due to their higher membrane aﬃnity (greater
hydrophobicity) at physiological pH and slower rate of
membrane insertion.17 Additionally, the 64Cu-NO2A-cyspHLIP
derivatives show decreased radioactivity accumulation in the
kidney from 4 h p.i. to 24 h p.i. which is due to clearance of the
drug rather than uptake, whereas the liver and spleen uptake
remains similar for the two time points. The liver and spleen
uptake may be due to loss of the 64Cu from the chelator,20
digestion of the radiotracer in vivo, or accumulation of intact
tracer in these organs. Further investigation of this uptake is
currently underway by investigating a pHLIPcys-NO2A
derivative that contains the cysteine residue on the internalized
portion of the peptide (C terminus), which could result in
lower liver and spleen uptake if the uptake in these organs is
due to loss of the 64Cu from the chelator after membrane
insertion.
From these results it becomes evident that introducing a
benzene ring in close proximity to the N-terminus of the
peptide sequence and using a negatively charged metal complex
should be avoided in pHLIP peptide-mediated tumor imaging
pharmaceuticals. Instead, conjugating to either the cysteine side
chain or utilizing a suitable linking group on the N-terminus
may improve tumor targeting of the synthesized pHLIP
peptide. These general guidelines may help explain the
improvements seen in this study and understand the results
from previous studies.
Two compounds from the 12 tracers included in this study
showed the greatest tumoral uptake and signiﬁcant tumor-to-
background contrast in the images throughout the imaging
studies: 64Cu-NO2A-cysVar3 and 18F-AlF-NO2A-cysVar3.
Therefore, we next investigated the in vivo properties of
these two tracers in PC3 and LNCaP tumor-bearing mice to
compare tumoral uptake with previous studies.10−12 In these
tumor models, the tumor accumulation of 64Cu-NO2A-cysVar3
and 18F-AlF-NO2A-cysVar3 was signiﬁcantly higher compared
to previous generations of PET isotope-labeled pHLIP
constructs, especially at 24 h p.i. (Figure S7). Of particular
note is the uptake of the 18F-py-click-6Ahx-WT reported by
Daumar et al.11 and 68Ga-DO3A-cysVar7 reported by Viola-
Villegas et al.12 Both of these previously reported compounds
show signiﬁcant uptake at 4 h p.i. and could be clinically useful.
By comparison of the tumor:tissue ratios with those of
previously reported compounds (Figure S8), the tumor:muscle
ratios at 4 h p.i. were 7.4 ± 1.3 (64Cu-NO2A-cysVar3), 6.9 ±
1.9 (18F-AlF-NO2A-cysVar3), 4 ± 2 (18F-py-click-6Ahx-WT),
and 1.1 ± 1.5 (68Ga-DO3A-cysVar7) in PC3 tumor-bearing
male nude mice; the tumor:bone ratios were 2.7 ± 0.6 (64Cu-
NO2A-cysVar3), 3.2 ± 0.7 (18F-AlF-NO2A-cysVar3), 1.3 ± 0.4
(18F-py-click-6Ahx-WT), and 0.4 ± 0.3 (68Ga-DO3A-cysVar7)
in PC3 tumor-bearing male nude mice. Additionally, the
tumor:muscle ratios in LNCaP tumor-bearing male nude mice
at 4 h p.i. were 6 ± 2 (64Cu-NO2A-cysVar3), 4.7 ± 0.9 (18F-
AlF-NO2A-cysVar3), and 6 ± 3 (18F-py-click-6Ahx-WT); the
tumor:bone ratios in LNCaP tumor-bearing male nude mice at
4 h p.i. were 4.2 ± 1.7 (64Cu-NO2A-cysVar3), 4.3 ± 1.1 (18F-
AlF-NO2A-cysVar3), and 1.8 ± 0.6 (18F-py-click-6Ahx-WT). In
each of these cases, the tumor ratios of the two lead compounds
from this study are much better than the 68Ga-DO3A-cysVar7,
which would result in improved image contrast. While the 18F-
py-click-6Ahx-WT had similar tumor:muscle ratios, the tumor:-
bone ratios were much lower than the two lead compounds in
both prostate cancer tumor models. The decreased tumor:bone
ratios may indicate that the previously reported 18F-py-click-
6Ahx-WT was more prone to deﬂuorination than the 18F-
labeled tracers presented in this study.
Despite the similar tumor-targeting properties, the prepara-
tion of 18F-py-click-6Ahx-WT requires two HPLC-based
separations and generates a volatile radioactive intermediate.
The preparation of either of the lead compounds from this
work, in contrast, did not required HPLC puriﬁcation or
heating beyond 80 °C which is optimal for rapid dose-on-
demand production of the tracers for patient trials. Thus, the
two lead compounds from this study appear to be the best
candidates for clinical translation because of their improved
biopharmaceutical properties and facile radiosynthesis.
Two other tumor types (melanoma and glioma) were
included in this study to determine if the high uptake of these
radiotracers seen in breast and prostate cancer models would
translate to other types of tumors. The lead compounds have
excellent tumor:background contrast in B16−F10 murine
melanoma tumor-bearing mice, which was useful to identify
very small tumors (<17 mg; ∼4 mm3) in the PET image.
Because of the contrast and high uptake, we plan to continue
investigating the use of the two lead compounds in metastatic
B16−F10 tumor models. For the brain tumor models, both an
orthotopic and a subcutaneous (ﬂank) brain tumor mouse
model indicated that the 18F-AlF-NO2A-cysVar3 was unable to
penetrate an intact BBB, but was able to target brain tumors
that had developed outside the BBB (Figure S5). Because this is
a peptide-based tracer, we did not expect the compound to be
able to cross an intact BBB; thus, these tracers may be useful in
identifying metastases and possibly brain tumors in situations of
compromised BBBs.
Previously, autoradiography was performed by Viola-Villegas
et al. in prostate tumor sections from excised PC3 and LNCaP
tumors in order to show diﬀerences in histology and tracer
uptake;12 thus, a similar study was performed with the uptake of
64Cu-NO2A-cysVar3 in the same tumor lines. Overall, the ex
vivo tumor sections show increased uptake of the 64Cu-NO2A-
cysVar3 in the necrotic regions of the LNCaP tumors (Figure
7). This may indicate that if necrosis is present, then uptake of
64Cu-NO2A-cysVar3 may increase, but is not the only
requirement. The ﬁndings here generally match the trend
found by Viola-Villegas et al. in prostate tumor sections.12
Additionally, the greater uptake in the allografted tumors may
indicate the relative overall tumor environment is less acidic
(higher) in the slower growing human cell lines investigated
(PC3 and LNCaP), but is more acidic (lower) in the faster
growing murine cell lines (B16−F10 and 4T1).
■ CONCLUSIONS
In our study, the NO2A-cysVar3 is the lead construct for
clinical investigation. This construct can be radiolabeled with
18F or 64Cu with similar pharmacokinetic properties. The
availability, limited dose exposure due to its short half-life, and
cost eﬀectiveness of 18F supports the utility of 18F-AlF-NO2A-
cysVar3 in the clinic. Nevertheless, 64Cu-NO2A-cysVar3 may
be more suitable for inpatient imaging (where the patient will
be in the clinic longer than 24 h) and in centers where the
availability of the PET scanner may impact the time when
patients are imaged. Clinical evaluation of these radiopharma-
ceuticals is currently underway.
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■ EXPERIMENTAL SECTION
The D-amino acid versions of NOTA-derivatized pHLIP
peptides were purchased from CS Bio (Menlo Park, CA)
with ≥95% purity (combination of both chelators and three
variants from Figure 2: NOTA-WT, NOTA-Var3, NOTA-Var7,
NO2A-cysWT, NO2A-cysVar3, and NO2A-cysVar7). All other
chemicals were purchased from commercial suppliers without
further puriﬁcation unless otherwise stated. Detailed method
descriptions are found in the Supporting Information.
Radiochemistry. General Labeling Methods for 64Cu-
NOTA-pHLIP. Following a preparation similar to that of Zeglis
et al.,21 64Cu was diluted in a 100 mM NH4OAc buﬀer (pH ∼
5.5) and reacted with a NOTA-pHLIP derivative at 80 °C for
15 min.
General Labeling Methods for 18F-AlF-NOTA-pHLIP.
Following a modiﬁed labeling method described by Dijkgraaf
et al.,22 18F from the cyclotron target water was concentrated
using a chromaﬁx cartridge into 0.1 mL of 0.4 M KHCO3 in
metal-free water. The pH was adjusted and 0.1 mL AcN added.
To this solution, AlCl3 (80 nmol) in 0.1 M NH4OAc buﬀer
(pH ∼ 4.1) was added. After 5 min, the NOTA-pHLIP
derivative was added and the reaction mixture reacted at 75 °C
for 15 min.
General Puriﬁcation. An Oasis HLB Plus Light or C18 Sep-
Pak Light cartridge (Waters, Milford, MA) was used to remove
unbound activity. The pure radiolabeled NOTA-pHLIP
derivatives were eluted with EtOH and diluted with sterile
phosphate buﬀered saline (PBS) with radiochemical purities
>93% before administration to animals.
Animal Models. Animal studies were conducted according
to an MSKCC IACUC-approved animal protocol. 4T1
(orthotopic breast cancer allografts of 1 × 106 cells surgically
implanted in the mammary fat pad) and B16−F10 (orthotopic
melanoma allografts of 1 × 105 cells injected intradermally on
the shoulder) tumors were orthotopically inoculated in media
in female BALB/c and C57Bl/6 mice (Charles River
Laboratories (CRL)), respectively. Additionally, PC3 (3 ×
106 cells) or LNCaP ((3−6) × 106 cells) tumors were
subcutaneously xenografted on the shoulder of athymic nude
male mice (CRL). Mice were used once tumor volumes were
approximately 90−300 mm3.
In Vivo Animal PET Imaging and Biodistribution. Mice
were injected with radiolabeled NOTA-pHLIP derivatives i.v.
(500−700 μCi/mouse for PET imaging studies and 25−100
μCi/mouse for biodistribution studies). All injections were less
than 200 μL with <10% EtOH in sterile PBS. PET images were
obtained with the mice under anesthesia in an Inveon PET-CT
or microPET Focus 120 (Siemens) at 0.5−48 h p.i. All images
were analyzed using ASIPro VM (Concorde Microsystems).
Dissections for ex vivo biodistribution were performed on mice
after CO2 asphyxiation or cervical dislocation while anesthe-
tized at reported time points. Weight of the syringe prior to
injection and after injection was used to determine the mass of
injectate. Activity of the syringe prior to injection and after
injection was used to determine the percent of injectate
administered. The mass injected was corrected by the percent
of radioactivity injected. Four to ﬁve aliquots (10 μL) were
weighed and counted as internal standards for each study. All of
the collected organs were counted using an automatic gamma
counter (Wizard 3″, PerkinElmer, Waltham, MA). The total
injected dose was found as the mass injected dose × fraction
radioactivity injected × internal standard average counts/g. The
percent injected dose (%ID) was determined as the counts for
the tissue × 100/total injected dose. The %ID/g was calculated
as the %ID/tissue weight. The average and standard deviation
of the %ID and %ID/g was determined using normal methods
(n − 1) for each set of mice.
Ex Vivo Autoradiography, Staining, and Microscopy.
Tumors were excised from the mouse, embedded into Tissue-
Plus O.C.T. (Scigen, Gardena, CA), stored at −20 °C until
sectioning, and cut in sequential 10 μm sections. Select sections
were exposed to autoradiography ﬁlm (Fujiﬁlm, GE Health-
care) for 1−3 days and read using a typhoon photographic ﬁlm
scanner (GE Healthcare). Additionally, sections were stained
with H&E for gross tumor microscopy and then scanned.
Biophysical Studies. Biophysical studies were conducted
on nonradioactive standards of the NOTA-pHLIP and NO2A-
cyspHLIP compounds. All experiments were conducted with a
5 μM to 1 mM construct to lipid ratio. State I (construct with
no liposomes in solution) and State II (construct in the
presence of liposomes) were measured at pH 8; for State III
(construct in the presence of liposomes), the pH of solution
was dropped to pH 4 using 2 M HCl. Experiments were
conducted in 10 mM phosphate buﬀer (Sigma-Aldrich) either
without additional ions or in the presence of physiological
levels of free magnesium and calcium (0.65 mM and 1.25 mM,
respectively).
Liposome Preparation. Large unilamellar vesicles were
prepared by extrusion. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phos-
phocholine (POPC; Avanti Polar Lipids) was dissolved in
chloroform at a concentration of 12.5 mg/mL, desolvated by
rotary evaporation, and dried under high vacuum for 2 h. The
phospholipid ﬁlm was then rehydrated in 10 mM phosphate
buﬀer (pH 8.0 with or without ions), vortexed, and extruded
15× through a 50 nm pore.
Steady-State Fluorescence. Tryptophan ﬂuorescence spec-
tra were measured using a PC1 ISS spectroﬂuorometer
(Champaign, IL) with temperature control set to 25 °C.
Fluorescence spectra were recorded with excitation and
emission slits set to 1 mm, using an excitation wavelength of
295 nm, with excitation and emission polarizers set to 54.7°
and 0°, respectively.
Steady-State Circular Dichroism. Circular dichroism
measurements were taken using a MOS-450 spectrometer
(Bio-Logic SAS, Claix, France) with temperature control set to
25 °C in the range of 190 to 260 nm with step of 1.0 nm.
pH Dependence. The pH-dependent insertion of the
construct population was investigated using the shift in position
of the wavelength of maximum intensity of the tryptophan
ﬂuorescence spectra varying pH conditions between 4 and 8.
The pH after addition of HCl was measured using an Orion
PerpHecT ROSS Combination pH Micro Electrode and an
Orion Dual Star pH and ISE Benchtop Meter (Thermo Fisher
Scientiﬁc). Tryptophan ﬂuorescence spectra were recorded at
each pH value and were analyzed using an online protein
ﬂuorescence and structural toolkit (PFAST) to obtain the
positions of spectral maxima (λmax). Finally, the positions of
λmax were plotted as a function of the various pHs and the
Henderson−Hasselbalch equation employed to ﬁt the data
λ λ= + λ λ−
+ −max max
2
1 10n K
max
1
max
2
(pH p ) , where λmax
1 and λmax
2 are the
positions of spectral maxima at the end and beginning of the
State II − State III transition, respectively, n is the cooperativity
parameter, and pK is the midpoint of transition.
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